Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanotek Biologics Deal Gives Green Cross Route To Russia

This article was originally published in PharmAsia News

Executive Summary

Following its entry into North America and China, Green Cross is set to make inroads into the rapidly growing Russian pharmaceutical market through a strategic partnership with Nanolek to commercialize the South Korean biopharmaceutical company’s biologics.

You may also be interested in...

Korea's Green Cross Sees Earnings Plunge As Flu Fears Wane

SEOUL - As widely expected, vaccine producer Green Cross, one of Korea's leading pharmas, has seen a sharp drop in its sales and net profit during the fourth quarter of last year

Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference

SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1

Green Cross Teams Up With MacroGenics For Bio-better Of Roche's Herceptin

SEOUL - South Korea's Green Cross has signed an agreement with Rockville, Maryland-based MacroGenics to develop and sell the latter's modified anti-breast cancer monoclonal antibody MGAH22 in Korea. MGAH22 is a modified "bio-better" of Roche's oncology agent Herceptin (trastuzumab)


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts